Dr. Steven Victor Announces ASAIO Has Published A Case Study Organized By ReGen Medical

MANHATTAN, N.Y. - Oct. 13, 2015 - PRLog -- Dr. Steven Victor, CEO of Regen Medical, PC, a New York regenerative medicine company, announced today that the Journal of the American Society for Artificial Internal Organs, has published a case study entitled “First in Man: Sternal Reconstruction with Autologous Stem Cells.” This study describes the first reported example in man of successful sternal reconstruction using adipose-derived stromal vascular fraction stem cells. These stromal vascular fraction cells (SVFCs) were provided to the treating cardiothoracic surgeon by Intellicell Biosciences.

Dr. Victor stated,  "I am pleased that the Journal of the American Society for Artificial Internal Organs has chosen to feature a case study involving the patented technology of Intellicell Biosciences to harvest SVFCs. The patient’s sternal nonunion was healed and closed within three months of treatment and we are looking forward to the impact that SVFCs will continue to have in the cardiac field.
We want to thank ReGen Medical, PC for making this case study possible.”

About Dr. Steven Victor MD:
Our founder and CEO, Dr. Steven Victor, is a leader in aesthetic dermatology and cellular medicine. His experience in researching, developing and providing treatment spans over thirty years. He is a clinical expert in groundbreaking anti­-aging and cellular therapy technologies, with a passion for creating safe, minimally invasive treatments that aid patients in living a longer, healthier, more beautiful life. His reputation for excellence has brought numerous worldwide celebrities, TV personalities and models to his practice.

Most recently and most notably, Dr. Victor has developed a state-of-the-art laboratory and a patented, proprietary technology for the efficient and reproducible separation of stromal vascular fraction cells containing Mesenchymal Stem Cells, from the vasculature (blood vessels) in adipose (fat) tissue. Learn more about Dr. Victor’s cellular therapy technology at www.regenmedicalpc.com

Medical Practitioner – Dr. Victor received his medical degree from New York Medical College and a Bachelor of Arts degree from NYU.

Educator – He has held hospital teaching appointments at New York University, New York Medical College, Beth Israel Medical Center and Lenox Hill Hospital.

Respected Expert – Has been featured in international and national media, discussing regenerative medicine, medical aesthetics and cosmetic dermatology, and was the consulting dermatologist to Elizabeth Arden and Clarins.

Innovator – Dr. Victor has developed a technology in cellular therapy patented for IntelliCell Biosciences and licensed by ReGen Medical, PC.

Author – He is also a co­-author of the book Ageless Beauty, A Dermatologist’s Secrets to Looking Younger Without Surgery (2003).

About ReGen Medical PC:
ReGen Medical is a premier wellness, longevity and aesthetic medical facility providing the most advanced cosmetic treatments in combination with the latest science driven bio-technology.

Located in the heart of Manhattan, it tailors its services to each patient ensuring their specific needs are met.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

CONTACT:

Public Relations
Anna Rhodes
Managing Director
Phone: 1 212 249 3050